1/12
08:27 am
kytx
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/12
08:00 am
kytx
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
Medium
Report
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
1/11
01:03 am
kytx
Kyverna Therapeutics (NASDAQ:KYTX) was upgraded by analysts at
Wall Stre
Medium
Report
Kyverna Therapeutics (NASDAQ:KYTX) was upgraded by analysts at
Wall Stre
1/8
09:37 pm
kytx
Aktis raises $318M in 2026's first biotech IPO [Yahoo! Finance]
Low
Report
Aktis raises $318M in 2026's first biotech IPO [Yahoo! Finance]
1/5
08:00 am
kytx
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
Medium
Report
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
1/3
01:08 am
kytx
Kyverna Therapeutics (NASDAQ:KYTX) was downgraded by analysts at
Wall St
Medium
Report
Kyverna Therapeutics (NASDAQ:KYTX) was downgraded by analysts at
Wall St
12/18
02:52 pm
kytx
Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies [Seeking Alpha]
Low
Report
Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies [Seeking Alpha]
12/17
09:24 am
kytx
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
Medium
Report
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
12/16
07:19 am
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
12/15
04:05 pm
kytx
Kyverna Therapeutics (NASDAQ:KYTX) was given a new $33.00 price target on by analysts at Morgan Stanley.
Low
Report
Kyverna Therapeutics (NASDAQ:KYTX) was given a new $33.00 price target on by analysts at Morgan Stanley.
12/15
04:01 pm
kytx
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
Medium
Report
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
12/15
12:07 pm
kytx
Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome [Seeking Alpha]
Low
Report
Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome [Seeking Alpha]
12/15
10:23 am
kytx
Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease [Yahoo! Finance]
Medium
Report
Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease [Yahoo! Finance]
12/15
06:40 am
kytx
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome [Yahoo! Finance]
Low
Report
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome [Yahoo! Finance]
12/15
06:30 am
kytx
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
Low
Report
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
12/14
03:02 pm
kytx
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome [Yahoo! Finance]
High
Report
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome [Yahoo! Finance]
12/14
02:30 pm
kytx
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
High
Report
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
12/13
01:10 am
kytx
Kyverna Therapeutics (NASDAQ:KYTX) was upgraded by analysts at
Wall Stre
High
Report
Kyverna Therapeutics (NASDAQ:KYTX) was upgraded by analysts at
Wall Stre
12/12
10:36 am
kytx
2 ‘Strong Buy' Biotech Stocks With 208% to 329% Upside Potential [Yahoo! Finance]
Medium
Report
2 ‘Strong Buy' Biotech Stocks With 208% to 329% Upside Potential [Yahoo! Finance]
12/9
04:25 pm
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/4
09:08 am
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
11/25
01:53 pm
kytx
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
12:28 pm
kytx
Kyverna Therapeutics GAAP EPS of -$0.85 misses by $0.04 [Seeking Alpha]
Medium
Report
Kyverna Therapeutics GAAP EPS of -$0.85 misses by $0.04 [Seeking Alpha]
11/12
07:10 pm
kytx
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Medium
Report
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/12
04:05 pm
kytx
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Medium
Report
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results